BLUE BELL, Pa., Sep 23, 2010 (BUSINESS WIRE) -- Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio scientists and collaborators of the company will present immune response and other important data for several of its DNA vaccines for infectious diseases at three major global vaccine conferences in late September and early October, 2010. Following are a list of the conferences and presentations:
Tuesday, Sept 28
Diverse Approaches to Malaria Vaccine Development: "Inducing potent humoral and cellular responses to multiple pre-erythocytic-stage antigens using pDNA." Dr. David B. Weiner, Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Pharmaceuticals
Wednesday, Sept. 29, 10:30am
Novel Immunogens and Inserts: "Co-delivery of mucosal chemokine plasmids in systemically administered DNA vaccines elicits systemic and mucosal immune responses in rhesus macaques." Dr.Michele Kutzler, Drexel University College of Medicine
Wednesday, Sept. 29, 1:30pm
Pre-Clinical and Early Clinical Trials: "Enhanced magnitude of immune responses induced by SIV antigens delivered by plasmid DNA via electroporation and boosted by recombinant adenovirus 5." Dr.Natalie Hutnick, University of Pennsylvania
In addition, Inovio and its collaborators will present five posters showcasing Inovio's novel DNA vaccine delivery technology and preclinical vaccine results during the AIDS Vaccine 2010 conference.
Sunday, Oct. 3, 4:30pm
Gene-based and subunit vaccines: "Potent as well as protective immune responses induced by highly engineered DNA vaccines delivered by CELLECTRA(R) EP in Nonhuman Primates and Humans." Dr. David B. Weiner, Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Pharmaceuticals
TBD
"VGX-3100: Induction of cellular and humoral responses in post-LEEP CIN 2/3 following immunotherapy with HPV16 & 18 SynCon(TM) DNA vaccines via electroporation." Dr. Niranjan Y. Sardesai, SVP, R&D, Inovio Pharmaceuticals
In addition to the oral presentations, Inovio and its collaborators will present two posters highlighting Inovio's preliminary pre-clinical vaccine results with target antigens in its research pipeline.
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon(TM) vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the six months ended June 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
SOURCE: Inovio Pharmaceuticals, Inc.